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1. Introduction 
Total hip replacement (THR), one of the most successful and cost effective surgical 
interventions introduced in the last 50 or so years in medicine and the second most common 
elective operation in the UK (Sheldon et al., 1996, Garellick et al., 1998), owes most of its 
success to the introduction of hard-on-soft arthroplasty by Charnley. Arthroplasty (from the 
Greek ‘arthrosis’ = ‘joint’ and ‘-plasty’ = ‘the making of’) describes the surgical reconstruction 
or replacement of a malformed, degenerated or traumatised joint. THR is the treatment of 
choice for conditions that affect both the articular surfaces (i.e. acetabulum and femur) of the 
hip joint. Worldwide, approximately one million artificial hips are implanted annually (Smith 
& Learmonth, 1996). Problems with polyethylene (PE) wear debris from soft-on-hard 
articulations (causing an infiltration of macrophages, eventually leading to destruction of bone 
and soft tissue and initiating loosening of the implant) led to the development of hard-on-hard 
bearing combinations for artificial hips as the latter produce minimal wear and therefore 
implant failure is delayed. 
Until recently, THRs have been reserved primarily for the elderly and with relatively short 
post-operative life expectancies there was no need for studies investigating the long term 
effects, since on average, prosthetic joints are relatively trouble-free for 10-15 years (Havelin 
et al., 2000). However, due to their success, a greater number of THRs are nowadays 
performed on increasingly younger, more active patients. In England a substantial 
proportion of THR patients (>12%, i.e. >10.000 individuals yearly) are below 60 (NHS, 2006). 
Bearing in mind that the use of artificial hips is more rigorous in younger patients and that 
life expectancy continues to increase, it is time that the question of possible adverse long 
term effects following implantation needs to be addressed. Most importantly, concerns for 
potential carcinogenicity of THRs is reasonable to be raised, since both soluble and 
particulate wear debris originating from the prostheses are biopersistant and are found 
systemically in the human body following the operation. In this chapter I discuss the 
proposed links between hip replacements and carcinogenesis to date by summarizing the 
relevant literature while presenting important background information regarding THRs, the 
generation of wear debris from hip prostheses, its biopersistence and the extent of its 
dissemination in the human body. This review is mainly focused on materials currently 
being used as bearing surfaces in artificial hips for younger patients. 
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2. Basic anatomy of the hip joint and indications for THR therapy 
The hip joint is a multiaxial ball and socket synovial joint formed between the spherical 
head of the femur and the hollow cup-shaped acetabulum of the pelvis, which in turn forms 
at the union of 3 pelvic bones (the ileum, ischium and pubis). The depth of the acetabulum is 
increased by a fibro-cartilaginous rim (labrum) which grips the head of the femur and 
secures it in the joint. The head of the femur is attached to the femur by a thin neck region. 
Both joint surfaces are covered with a strong layer of articular hyaline cartilage, except for a 
small area in the head of the femur, the fovea or pit, from which an intracapsular ligament 
attaches directly to the acetabulum. A strong fibrous capsule is attached to the rim of the 
articular cartilage, enclosing the joint cavity. Thickened strands of this capsule form 
ligaments which support the joint. The whole joint cavity is lined by a membrane, the 
synovium, the cells of which secrete an oily fluid that lubricates the articulating surfaces and 
allows smooth movement of the ball within the socket. A network of blood vessels, lymph 
vessels and nerves is also present (Standring, 2004). The hip joint(s) form the primary 
connection between the lower limb(s) and the axial skeleton of the trunk and pelvis. Its 
primary function is to support the weight of the body in both static (e.g. standing) and 
dynamic (e.g. walking or running) postures. Its strong but loose fibrous capsule permits a 
large range of movement (second only to the shoulder). 
Joint injuries are caused either by trauma or by gradual wear and tear due to aging and/or 
congenital predisposing factors. The hip joint frequently succumbs to degenerative and 
inflammatory diseases causing severe pain and stiffness, e.g. osteoarthritis and rheumatoid 
arthritis. Osteoarthritis, the most common form of chronic joint disease, results primarily 
from destruction and/or degeneration of the cartilage at the articular surfaces with age. In 
younger people, it may be the result of congenital dysplasia and/or dislocation, damage 
caused by fracture, previous inflammation etc. In fact, any situation which puts an unusual 
stress on the joint(s) can predispose to osteoarthritis (Flugsrud et al., 2002). Rheumatoid 
arthritis is an inflammatory disease of the connective tissue. It is more common in women 
and presents mainly between the ages of 25 and 55. Affected joints become swollen and 
tender due to inflammation of the synovium and escape of synovial fluid into the joint 
cavity. Although the disease often burns itself out in time, damaged joints continue to 
disintegrate, causing severe pain and stiffness. Hip joint fractures can occur at any age 
although they are more frequent in the elderly as they are closely associated with 
osteoporosis (i.e. a reduction in bone density due to decreased bone formation and/or 
increased bone resorption resulting in brittle bones). Osteoporosis’ incidence increases with 
age and is most commonly seen in post-menopausal women but it can also begin very early 
in life. THR therapy aims to relieve pain and increases the patient’s quality of life by 
comprehensively restoring the structure and function of the hip joint via complete 
replacement of the head of the femur and the lining of the joint socket on the pelvis with 
artificial materials (Smith & Learmonth, 1996, Garellick et al., 1998).  
3. A brief history of THR and the modern artificial hips – Design & materials 
The first recorded THR was performed in 1938 by Philip Wiles, using a total hip made 
entirely of stainless steel. The acetabular cup was fixed with two screws while the femoral 
component was secured by a bolt that passed through the neck of the femur (Amstutz & 
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Grigoris, 1996). The next major development was in 1951; the McKee-Farrar total hip was 
again made entirely of stainless steel however the stem was fixed using acrylic cement. In 
the late 1950s McKee and Farrar started operating more frequently with a Cobalt-based 
alloy (CoCrMo) as the principle bearing material. Various types of prostheses, including the 
McKee-Farrar, Ring, Stanmore and Muller designs, employed this bearing surface during 
the 1950s-1960s and it was not until the 1970s that metal-on-metal (MOM) articulation lost 
favour, mainly due to the successful design of the Charnley artificial hip which completely 
replaced all the other designs (Charnley, 1972). Accelerated corrosion because of improper 
selection of materials or faulty fabrication techniques (Jacobs et al., 1998a), and concerns 
about possible carcinogenesis (Heath et al., 1971), metal sensitivity and high infection rates 
eventually led to the abandonment of MOM articulation as soon as a better option was 
available (Amstutz & Grigoris, 1996). 
While studying animal joint lubrication, Charnley realized that a cartilage substitute was 
necessary in order to allow artificial joints to function at the extreme low-friction level, as 
seen in nature. His innovative design consisted of a metal (hard) femoral component, a 
plastic (soft) acetabular component and bone cement. In 1958, he replaced an eroded 
arthritic socket with a thick walled Teflon cup, within which a small femoral head 
articulated, attached to an acrylic-fixed stem. The small (22.25mm) femoral head chosen was 
aiming for a decreased wear rate, however it had relatively poor stability (the larger the 
head of a replacement, the less likely it is to dislocate, but the more wear debris will be 
produced due to the increased articulating surface area) and failed quickly due to massive 
inflammation following PE wear production. In 1961, Charnley substituted Teflon with high 
molecular weight polyethylene (HMWPE) which is 500-1000 times more resistant to wear. In 
the 1970s, Boutin was the first to introduce alumina ceramic as a bearing surface in 
orthopaedics (Boutin, 1971). Ceramic-on-ceramic (COC) articulations produced minimal 
wear however early results were discouraging as these prostheses were very prone to 
fractures (Boutin et al., 1988). Thus, for over two decades, the Charnley Low Friction 
Arthroplasty design was the preferred system worldwide, far surpassing the other available 
options. Thousands of people were successfully relieved from their hip pain and the long-
term results became more predictable. John Charnley was knighted for his efforts (Cornell & 
Ranawat, 1986a, b) and many similar designs (pioneered by Charnley) followed.  
The current/modern artificial hips have three parts: (a) a rod or stem, which fits into the 
femur to provide stability and is usually made from metal (Ti- or CoCr-based alloys) while 
cement (poly-methyl-methacrylate) is sometimes used to fix it firmly in place; (b) a head or 
ball, which replaces the spherical head of the femur and is made of either hard, smooth 
metal (usually CoCr alloy) or ceramic (usually Al2O3) and (c) a shell or cup which replaces 
the faulty hip socket and allows bone to grow onto. Sometimes, a liner is used that locks into 
the shell and this in turn articulates with the ball. The cup can therefore be made of one or 
more materials, but the actual articulating surface that touches the ball is commonly made of 
CoCr-alloy, alumina or ultra high-molecular weight-polyethylene (UHMWPE). Each part is 
manufactured in various sizes in order to accommodate various body sizes and types. In 
some designs the stem and ball are one piece whilst other designs are modular, allowing 
additional customization for a better fit. In the U.S., all implant devices must be approved 
by the Food & Drugs Authority (FDA) and similar purpose governing bodies exist 
worldwide. In the U.K. approval must be given by the Medicines & Healthcare products 
www.intechopen.com
 
Orthopedic Surgery 
 
104 
Regulatory Agency (MHRA) prior to clinical use of any THR implants. It is worth 
mentioning that an implant device may be approved in one country but not in another; e.g. 
COC total hips were widely used in Europe before they were made available in the U.S. (see 
www.mhra.gov.uk and www.fda.gov/Medical Devices).  
In summary, finally, surface choices in modern THRs can be divided into hard-on-soft 
metal-on-polyethylene (MOP) or ceramic-on-polyethylene (COP) and hard-on-hard metal-
on-metal (MOM) and ceramic-on-ceramic (COC) bearings. 
4. Why do implanted artificial hips fail after all? 
The ideal implant should stay in situ and function trouble-free indefinitely or at least for the 
whole of a patient’s life. However, this is not an ideal world and revision operations 
following THRs are often needed after 10-15 years if not sooner (Jacobs et al., 1998b). So why 
do hip prostheses fail? Initial acute complications following THRs include improper 
placement, cement extrusion and dislocation. Although dislocation can also occur as a late 
complication, it is most common in the immediate postoperative period (Manaster, 1996). 
Late complications include failure of any of the components of the prosthesis, mechanical 
(aseptic) loosening, bone fracture, heterotopic ossification (bone formation), loosening 
following infection and osteolysis (also termed aggressive granulomatosis or debris 
synovitis) (Tigges et al., 1994). In approximately 20% of patients, the artificial hip becomes 
loose within 20 years after implantation (Doorn et al., 1996a, Doorn et al., 1996b) while 
aseptic loosening in THR accounts for approximately 75% of revision procedures (Amstutz 
et al., 1992). In an early study, Dobbs et al evaluated the survival of THR prostheses by 
measuring whether they were still in situ; MOM articulations were found to have lower 
survival rates than MOP ones (53% and 88% respectively); nonetheless, the predominant 
reason for failure/revision in both cases appeared to be loosening of the prostheses’ 
components and authors blamed wear production for triggering osteolysis (Dobbs, 1980).  
Initially termed ‘cement disease’ (Jones & Hungerford, 1987), osteolysis is now understood 
to be a biological response to particulate wear debris and may originate at several locations 
around a THR. Willert was among the first to hypothesize that aseptic loosening of THRs 
was caused by the local macrophage response to wear debris (Willert, 1977). Goldring et al 
subsequently described the synovial-like nature of the bone-implant interface in patients 
with loose THRs and showed that cells within the periprosthetic membrane had the capacity 
to produce large amounts of several ‘bone resorbing factors’ (Goldring et al., 1983). 
Although these initial reports were in cemented implants, similar processes have been 
identified recently in cementless implants (Ingham & Fisher, 2005). Interestingly, Havelin et 
al reported a significant increase in the annual number of revision operations in Norway 
mainly due to an increase of wear debris production and osteolysis without loosening. This 
finding presents a different situation to what was observed in earlier years, where most 
prostheses failed after aseptic loosening of their components (Havelin et al., 2000). 
Osteolysis remains the main problem of THRs leading to revision surgery and a plethora of 
research studies have identified the generation of particulate wear debris from the 
articulating surfaces as a key factor. The amount of wear particles that are generated, their 
chemical composition, size and shape influence the induction of osteolysis (Meneghini et al., 
2005). Micron and submicron wear particles (particularly of PE) have been identified as the 
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main cause of loosening of artificial hips, following osteolysis (Ingham & Fisher, 2000). The 
current hypothesis is that particulate wear debris released from the prostheses can invoke a 
biological response in the surrounding tissue. Adjacent to THRs, one can find synovial 
tissue, fibrous tissue, lymphocytes (occasionally) and foreign-body inflammatory cells 
(macrophages and giant cells) that are present roughly in proportion to the number of 
particles surrounding the prosthesis (Schmalzried & Callaghan, 1999). The macrophages 
appear to be the most relevant and important cells with respect to this biological reaction. 
As wear particles are released, macrophages ingest them in an attempt to clear them, 
become stimulated and release cytokines. The inflammatory response is marked by the 
accumulation of more macrophages at the implant site attracted via released cytokines 
(Ingham & Fisher, 2005). A chain of cytochemical events leads to the production of foreign 
body giant cells that release chemical mediators able to activate osteoclasts (Wang et al., 
1997). During osteolysis, the activated osteoclasts resorb bone, with subsequent loss of 
integrity of the implant-bone interface, resulting in loosening of the implant and/or cyst 
formation and finally implant failure (Archibeck et al., 2000, Horowitz et al., 1993, 
Schmalzried et al., 1992, Wang et al., 1997). The number and the size of the wear particles 
appear to be the most important factors in determining the potential to elicit a biological 
response (Ingham & Fisher, 2000, 2005). Importantly, aseptic loosening and/or osteolysis 
requiring revision have also been reported for hard-on-hard, minimally wearing THRs 
using MOM and COC bearings (Harris, 1994, Yoon et al., 1998).  
5. Modes of wear and the generation of different types of wear debris from 
hip prostheses 
Wear is the removal of material that occurs as a result of the motion between two opposing 
surfaces, under load (Schmalzried & Callaghan, 1999). In THRs, these can be either the 
primary bearing surfaces of an articulating couple or secondary surfaces. The conditions 
under which the prosthesis was functioning when the wear occurred have been termed the 
wear modes. Mode 1 wear results from the motion of two primary bearing surfaces against 
each other, as intended; this is unavoidable. Mode 2 wear results from a primary bearing 
surface moving against a secondary surface that it was not intended to come in contact with 
(e.g. when a femoral head penetrates a modular PE liner and articulates with its metal 
backing). Mode 3 wear results from primary surfaces sliding against each other but with 
third body particles interposed (thus the contaminant particles directly abrade one or both 
of the primary surfaces which are in turn transiently or permanently roughened, leading to 
a higher mode 1 wear rate). Mode 4 wear results from rubbing together two secondary 
surfaces (e.g. a liner with a backing) and particulate debris generated this way can migrate 
to the primary bearing surfaces leading to third body wear. 
There are four fundamental mechanisms through which wear debris can be generated: 
adhesion, abrasion, corrosion and fatigue. Adhesion involves the bonding of opposing 
surfaces when they are pressed together under load. Adhesive wear occurs when fragments 
usually from the weaker of two relatively smooth bearing surfaces break off and adhere to 
the opposing surface. A so-called transfer film may be formed, whose disruption and 
reformation may lead to extreme fluctuations in wear rate (McKellop et al., 1981). Abrasion 
is the mechanical process of surface grinding that takes place as a result of friction. Abrasive 
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wear occurs when asperities found on a relatively hard articulating surface cut and plough 
through a softer/smoother surface during the sliding motion, forming a series of grooves in 
the smoother surface. This results in the removal of material. The same process can also take 
place when other wear particles (e.g. cement), generated elsewhere, are caught between two 
bearing surfaces and exacerbate the wear process by scratching and scoring them; wear 
produced this way is called ‘third body’ (Sedel, 1992, Hamadouche et al., 2002). Corrosion is 
the deterioration of essential properties in a material due to reactions with its surroundings. 
There are several types of corrosive processes and corrosive wear can occur in the presence 
of a ‘hostile’ environment such as the human body. Regarding bearing surfaces, corrosion 
products can form a passivation layer which is continuously worn away by the sliding 
action of the articulating surfaces; thus corrosion can progress further generating both 
soluble and particulate wear debris. Fatigue arises when local stresses exceed the fatigue 
strength of a material, leading to its failure after a certain number of loading cycles and the 
release of wear debris from its surface and/or its fracture. In articulating surfaces, fatigue 
wear occurs during repeated sliding or rolling over the same area, in the presence of local 
surface features or bearing pair incongruities (i.e. unmatches). This produces accumulations 
of concentrated local cyclic stresses which exceed the fatigue limit of either material in the 
wear couple. Such concentrated cyclic surface loading leads to the formation of surface and 
subsurface cracks which can lead to surface break-up and the release of large fragments 
(Schmalzried & Callaghan, 1999). 
Notably, deformation of any of the bearing surfaces is expected to result in increased (Mode 
1) wear. Acetabular (component) deformation can be observed as a consequence of the 
press-fit technique, which is employed to fix equatorial over-sized implant cups in place 
without cement (Squire et al., 2006). As completely spherical cups have a considerable risk 
of being pushed out of the acetabulum due to the so called ‘rebound effect’ (combination of 
strong forces all around the cup), over-sizing cups around their equator allows a more 
reliable fixation by compression forces only. Nonetheless, cup deformation could adversely 
affect the bearing clearance (Springer et al., 2011) and thus the fluid film lubrication of MOM 
bearings, possibly leading to increased adhesive and/or abrasive wear. Deformation has 
also been implicated during difficult intra operative assembly of COC bearings (Langdown 
et al., 2007). 
In general, one can discriminate between particulate and soluble wear debris. Evidently, 
particulate wear debris can be produced by any of the above described wear mechanisms 
while soluble wear can occur only by the corrosive wear mechanism and basically consist of 
soluble ionic forms of metals, either from the implant surface itself or from the surface of 
released wear particles. Particulate corrosion debris is also generated by an electrochemical 
process in which metal ions released from an implant surface subsequently form metal salt 
precipitates. Such corrosion products may be generated from any metal surface but most 
commonly originate from MOM modular interfaces (Urban et al., 2004). Importantly, the 
generation of wear debris in a prosthetic hip from different mechanisms (described above) 
can occur either simultaneously or at different times over the lifetime of the prosthesis. 
6. Wear rates and the choice of modern bearings for young patients 
In vivo measurements from tissue retrieval studies often report on the amount of the 
prostheses debris produced (either particle mass or particle number) per gram of dried 
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tissue. Such investigations have shown that the number of wear particles surrounding THRs 
can range from 8.5x108 to 5.7x1011 per gram of dry tissue (Hirakawa et al., 1996). However, 
given that the concentration of wear debris decreases with increasing distance from the 
bearing surfaces and that a great amount of wear particles may not stay adjacent to the 
prostheses but rather be carried to very distant sites (see section 7), the adequacy of such 
measurements for the calculation of wear rates in vivo is questionable. Wear rates in vivo 
can be perhaps more adequately calculated using measurements of linear or volumetric 
wear from retrieved implants. Linear wear is reported in length units and values represent 
the depth of several ridges found on randomly chosen sample areas from the surface of 
retrieved components. Volumetric wear can be calculated from numerous linear wear 
measurements, using certain equations/formulas and assuming that the femoral ball (or 
acetabular lining) is originally a perfect sphere with a radius to best fit non-worn regions of 
each component (McKellop et al., 1996). 
In vitro hip simulator studies report wear rates per million cycles (Mc), since 1 Mc is thought 
to correspond to an implant’s moderate use for a year. In fact, such studies could be 
considered more accurate, since wear debris can in fact be collected. Wear can also be 
presented as weight loss and then converted to volumetric wear using the alloy’s density. 
However, questions have arisen as to the correspondence between the wear particles 
generated in vitro and those observed clinically in vivo (Savio et al., 1994). Nevertheless, hip 
simulator studies have proven particularly useful in identifying the wear pattern/profile of 
total hip systems; thus such studies have shown that unlike MOP systems which show 
linear ratios of wear over time, modern MOM prostheses have an early high wear ratio 
phase (run-in) followed by a lower wear ratio phase (steady-state) (Anissian et al., 2001). 
The same biphasic profile is observed also with modern COC articulations (Hatton et al., 
2002) and it is speculated that the initial wear phase is due to a polishing effect resulting 
from the motion of the head against the cup (Mode 1 wear) while the following phase is 
mostly due to third body wear. Hard-on-soft Charnley type couples like MOP have a single, 
constant rate of wear production since there is no ‘polishing effect’ i.e. it is the soft lining of 
the cup that always wears out.  
PE wear rates from MOP articulations reported both in vivo and in vitro range in general 
from 30-100mm3 per year. In the U.S., COP is the most common alternative bearing 
combination used in THR patients as it has been shown to reduce wear rates when 
compared with conventional MOP by 10% to 50% for periods exceeding 10 years (Jazrawi et 
al., 1998). However, other studies have not reported significant differences between MOP 
and COP wear rates (Schmalzried et al., 1998). Anissian et al calculated the run-in and 
steady-state wear rates of modern MOM articulations to be 2.22mm3/Mc and 1.0mm3/Mc, 
respectively. However, higher wear rates have been estimated from in vivo studies. 
McKellop et al concluded that the long term maximum wear rates of any design could be 
approximately 6µm per year - corresponding to a maximum mean volumetric wear of 6mm3 
metal particles per year (McKellop et al., 1996). One reason for the differences observed 
between in vivo and in vitro reported wear rates could be the nature of the lubricant used in 
simulators. The tribologic performance of a joint largely depends on the existence of a fluid 
(lubricant) film and the amount of coverage it confers to its surfaces and lubrication has a 
major influence on the amount of abrasive and especially adhesive wear (Walker, 1971). 
Another confounding variable appears to be the presence of surface coatings, which have 
been reported on both ceramic and metallic implants (Streicher et al., 1996, Lu & McKellop, 
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1997). It may be that the bearing surfaces in a hip simulator are actually articulating on such 
(smoother) coatings instead of the implant surfaces. Using low protein serum as a synovial 
fluid substitute, adding EDTA to reduce protein precipitates and running simulator tests at 
speeds that prevent heat generation are some of the modifications thought to result in 
decreased coating phenomena (Medley et al., 1996). Chan et al concluded that low surface 
roughness and small clearance between the head and cup are necessary for adequate fluid 
film lubrication and therefore for less wear production to occur; they suggested that if these 
parameters are optimal, all other engineering and manufacturing factors do not have a 
significant effect on the production of wear debris. Their simulator tests also showed that 
the volumetric wear of MOM articulation is 2000 times smaller than that of MOP 
articulation (Chan et al., 1999).  
In more recent hip simulator studies a technique called microseparation is employed, where 
the ball and socket separate slightly during the swing phase of gait, to produce (higher) 
wear rates that are more relevant clinically (i.e. are similar to the ones reported in vivo). It 
has been proposed that microseparation could occur in any hip prosthesis and it may be 
involved in the initiation of ‘stripe’ wear, a small band of wear observed to occur around the 
rim of acetabular cups in retrieved COC hip prostheses (Mittelmeier & Heisel, 1992). Neck 
and socket impingement is another way of generating stripe wear (Nizard et al., 1992). 
Nevelos et al, by introducing microseparation of the COC prostheses, reproduced for the 
first time clinically relevant wear rates (typically 1-5mm3 per annum), wear patterns and 
mechanisms (Nevelos et al., 1999). Other microseparation studies reported wear rates of 1-
2mm3/Mc (1.24mm3/Mc for modern prostheses and 1.74m m3/Mc for the first generation 
ones). The wear stripe often seen clinically on the femoral head was reproduced on both 
prosthesis types. The degree of rim contact depended on clearance and the authors 
postulated that clinically, microseparation may depend on factors like components’ 
alignment, position, soft tissue tension and muscle forces. Interestingly, two size-ranges of 
particles were found under in vitro microseparation testing: small (nanometre scale) and 
large (micrometre scale) particles (Tipper et al., 2002). Nanometre sized ceramic wear 
particles were first described in periprosthetic tissues in a study that also revealed a bimodal 
size distribution of alumina ceramic particles in vivo (Hatton et al., 2002). 
According to the above, it is evident that hard-on-soft Charnley type bearings demonstrate 
more wear for the same time period than hard-on-hard bearings (MOM and COC) as 
predicted, but are less susceptible to catastrophic failure. Modern hard-on-hard surfaces are 
mainly only sensitive to failure due to surgical technique (e.g. fixation, component 
positioning). Artificial hips that produce little wear are thought to be more durable and have 
a lesser risk for osteolysis, loosening and revision; hence, given a correct surgical 
implantation technique, modern hard-on-hard bearings are the preferred choice for 
younger, more active patients who have good quality bone tissue (Figure 1). Judging by 
wear debris production rate alone, ceramics provide the most desirable bearing surfaces 
(Savio et al., 1994) with alumina COC THRs having the lowest wear rates of any bearing 
surface combinations (Boutin et al., 1988). It has been calculated that the debris produced 
from an alumina-alumina THR where the femoral head is not too small, no stress risers 
occur from implantation, the acetabular cup is aligned properly, and an adequate clearance 
is maintained between the ceramic components may be as little as 1/4000 that of an 
equivalent MOP design (Sedel, 1992, Hamadouche & Sedel, 2000, Hamadouche et al., 2002). 
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Fig. 1. Volumetric wear rates (estimates) of modern THR cup and head combinations. Data 
taken from Heisel et al., 2004. 
Savio et al reviewed and compared descriptions of wear debris from many in vivo 
(revisions, autopsies) and in vitro (hip simulators) sources. The authors concluded that the 
type (composition) of THR materials plays a critical role in regards to the size, shape, 
volume and number of particles that are produced both in vivo and in vitro. More 
specifically, they hypothesised that the size of wear particles (minimum wear diameter) 
should be inversely proportional to a material’s modulus of elasticity (i.e. its hardness) and 
they have consequently predicted that ceramic wear particles should be the smallest, 
polymeric ones the largest and metallic ones of an intermediate size (Savio et al., 1994). 
Simulator tests (Chan et al., 1999) support the above hypothesis and so do analyses of 
particles that are produced in vivo (Doorn et al., 1998). Nonetheless, hard-on-hard bearings, 
although producing far smaller volumes of wear than conventional Charnley type couples, 
may produce a similar active total surface area of debris. The very small (nanometre) size of 
metallic debris released by MOM bearings (Archibeck et al., 2000), combined with the fact 
that the bioavailability of metal is thought to be a function of the total surface area of the 
released debris rather than on its volume or weight (Shanbhag et al., 1997), casts doubt on 
the supposition that the net adverse biologic response will be reduced by modern MOM 
designs even though the volumetric wear is reduced. COC articulations are also reported to 
release nanometre sized particles (Hatton et al., 2002).  
In addition to abrasive, adhesive and surface fatigue wear, metal alloys may suffer from 
corrosion. Corrosion can affect the whole surface of the implant or just a specific region (e.g. 
could be confined to an area of wear from mechanical stress). It is estimated that 30µg of 
metal ions (i.e. soluble wear) may be released from a prosthetic hip each day (Hennig et al., 
1992, Merritt & Brown, 1996). Ions are shown to react with other molecules forming several 
types of particulate corrosion wear. Jacobs et al analysed particulate corrosion products 
from retrieved implants and surrounding tissues. Particles of metal oxides, metal chlorides, 
and chromium phosphate corrosion products were identified on implants of 10 designs 
www.intechopen.com
 
Orthopedic Surgery 
 
110 
from 6 manufacturers. The most abundant solid corrosion product was an amorphous 
chromium orthophosphate hydrate-rich material (Jacobs et al., 1995). 
7. Dissemination and biopersistance of wear debris from implanted artificial 
hips 
As mentioned, wear debris can be both soluble (ions) and particulate. Ions may only be 
formed from metal components of artificial hips as they are the result of corrosion. 
Importantly, even in COC articulations, the stem is usually made of metal (Co-based or 
Ti-based alloy) and therefore, the existence of corrosion wear (both soluble and 
particulate) is applicable to all modern prostheses. Ions may stay bound to local tissue or 
bind to protein moieties that are transported via the bloodstream and lymphatics to 
remote organs. In an early post-mortem study, an increase in the concentrations of Co and 
Cr in remote tissues (liver and spleen) of a patient with bilateral Co-based alloy total hip 
components was reported; interestingly, Cr was found in a higher level than Co (Dobbs & 
Minski, 1980). Michel et al also reported on two post-mortem specimens with CoCr alloy 
components: in both cases high levels of Co and Cr were detected in adjacent tissues 
while a wide systemic effect was observed with increased concentrations of Co found in 
the heart, liver, spleen and lymphatic tissue and of Cr in the aorta, heart, liver, pancreas 
and spleen (Michel et al., 1991). 
Elevated levels of Co and Cr ions in the serum, blood and/or urine of patients have been 
reported numerous times following both MOP and MOM THRs. In an early cohort study 
Black et al showed that Cr levels increased significantly (peaked) immediately after primary 
THRs; this peak was reduced six months post-operatively but it did not fall below control 
levels (Black et al., 1983). After a similar study, Sunderman et al suggested that a substantial 
increase of serum and urine Co levels seen in two patients was associated with loosening of 
their prosthesis (Sunderman et al., 1989). In a later retrospective study whole blood and 
serum were analysed from CoCr alloy MOP THR patients who had their artificial hips in 
place for up to 18 years. None of the devices were loose and no increase in the serum levels 
of Cr was documented, however, in 4 patients massive Co enrichments were seen as a 
consequence of implant corrosion while the levels of Co in the serum were significantly 
higher than controls up to more than 10 years postoperatively; moreover, significant Co and 
Cr enrichment was seen in several tissues and organs (Michel et al., 1991). Not surprisingly, 
joint failure can result in large increases in the amount of soluble metal ions detected in 
urine and/or blood (Jacobs et al., 1998a). According to Schaffer et al the levels of both Co 
and Cr in blood and urine increase continuously; at 2-3 years post-operatively more than a 
quarter of the patients retrospectively studied exceeded German occupational exposure 
limits (Schaffer et al., 1999). A more recent study showed a steady increase in both metal 
elements for up to 2-3 years postoperatively, depending on the type/brand of metal alloy, 
while subsequently metal levels declined although still remaining markedly above control 
levels (i.e. immediately after the operation). Thus, it has been proposed that the rises and 
declines of metal levels over time are the result of biomechanical influences on the implant’s 
tribology (Lhotka et al., 2003). Simulation experiments support this view, since the pattern 
of metal levels observed in the blood and urine of MOM patients correlate with the 
(biphasic) wear pattern of the prosthesis per se (Anissian et al., 2001).  
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Importantly, Jacobs et al reported that younger patients had significantly higher levels of 
systemic metal release than older patients and postulated a more active lifestyle as the 
underlying factor (Jacobs et al., 1998a). A recent study by Dunstan et al in young (mean age 
45 years) patients supports this view; moreover, it shows that MOM articulations released 
significantly higher levels of Co and Cr when compared to MOP ones while further 
elevation of metal levels was observed in patients with loose MOM THRs (Dunstan et al., 
2005). Several in vivo and simulator studies have presented evidence that higher patient 
activity has as a result higher wear rates. Hence, it has been proposed that wear is a function 
of use, not time (Schmalzried et al., 2000). The case of a long distance runner with a MOM 
artificial hip supports this view: Metal (Co) levels in his blood were increased following 
completion of a marathon run and returned back to baseline levels 4 weeks later (Brodner et 
al., 2003). A contradictory study, after monitoring 7 recipients of well functioning MOM 
hips during a 2 week long physical activity challenge, suggested that serum metal levels are 
not affected by patient activity; therefore periodic measurements of serum ion levels could 
be used to monitor the tribologic (lubrication, friction, and wear) performance of MOM 
bearings without adjusting for patient activity (Heisel et al., 2005). However, the low 
number of participants, the use of only one external control and the fact that patients were 
not monitored past this period of physical exercise coupled with the existence of other 
contradictory reports (e.g. the case of the marathon runner) show that a correlation between 
MOM patient activity and systemic metal release can neither be proven nor excluded. When 
Jacobs et al explored the prospects for using blood, serum and/or urine metal levels to 
monitor the performance of MOM THRs, they concluded that it would be premature to 
recommend metal concentration analysis on a routine clinical basis since interpretation of 
values requires an extensive database with correlative clinical information (Jacobs et al., 
2004). In summary, leaching of soluble wear (metal ions) following primary THR is not an 
occurrence of merely local significance, but one that affects the trace element status of the 
entire organism and over extended periods of time.  
Particulate wear from artificial hip joints is also shown to be biopersistant and capable of 
systemic dissemination. Particulate corrosion debris (metal precipitates) from modular 
MOM junctions have been found locally and in sites remote from the hip (Urban et al., 
1994). Cr phosphate particles have been found in the liver, spleen and para-aortic lymph 
nodes of patients with corroded but otherwise successful THRs (Jacobs et al., 1995). In a 
post-mortem study, Case et al reported an accumulation of wear particles in periprosthetic 
tissues and a systemic dissemination of huge numbers of sub-microscopic metal particles 
within the bone marrow, the local and distal lymph nodes, the liver and the spleen; in one 
case even in the frontal cortex of the brain. Interestingly, PE debris was not detected in these 
remote sites, despite its usual abundance in periprosthetic tissues, while the levels of metal 
were higher in the subjects that had a loose, worn implant (Case et al., 1994). A major 
parameter affecting the dissemination of particles in various tissues is their size; while 
bigger particles stay close to the periprosthetic tissues, smaller particles can travel further 
(Savio et al., 1994). Dissemination of THR metallic wear particles to the liver, spleen and 
abdominal lymph nodes was identified in other later studies (Shea et al., 1997, Urban et 
al., 2000). A recent post-mortem analysis showed that metallic particles were present in 
the liver and spleen of 73% of patients with a prior failure and revision of their THR. 
Particles generated by previous component failures were present in the liver or spleen a 
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decade or more later and suggesting that particle deposition in the organs is cumulative 
(Urban et al., 2004). 
The dissemination properties and systemic effects of ceramic wear debris remain unknown. 
Because ceramics are insoluble in biological media (i.e. there is no production of 
ions/corrosion products at physiological pH), biocompatibility concerns do not relate to 
soluble wear debris. Although there are no reports of systemic dissemination of ceramic 
particles, ceramic particles have been observed in periprosthetic tissues (Savio et al., 1994). 
Similarities of their pale colour to the normal colour of tissues may mean that dissemination 
of particles to distant sites is harder to identify in the case of ceramics. The low wear rates 
and the very recent clinical use of COC articulations might also explain the absence of such 
reports. Based on reports on their observed size and shape however, there is no reason to 
believe that ceramic particles could not systemically disseminate and accumulate with time 
in various parts of our bodies, just as metal particles do.  
8. Proposed links between total hip replacements and cancer 
Given that wear debris from THR implants can disseminate (locally and systemically) and 
are biopersistant (mainly particulates), their carcinogenic potential is a real concern; 
especially as their use in younger patients, who may have a post-operative life expectancy of 
more than 30 years, is constantly increasing. Hard-on-hard bearings (i.e. MOM and COC) 
are usually the preferable option for such patients because they have been shown to 
generate less wear debris compared to conventional Charnley-type prostheses and are 
therefore thought to have less of a risk for early implant failure. But even for successful, 
durable THRs with minimal wear rates, the production and accumulation of wear debris 
over time cannot be avoided; and notably the use of a THR implant will inevitably be more 
rigorous and last longer in younger patients. The International Agency for Research on 
Cancer (IARC), a body within the World Health Organization (WHO) responsible for 
evaluating carcinogenic risks to humans, in a recent evaluation of surgical implants and 
other foreign bodies implanted (WHO, 1999) categorized all foreign bodies of Co-based, Cr-
based and Ti-based alloys in Group 3, i.e. ‘not classifiable as to their carcinogenicity to 
humans’. Ceramic implants were also under the same group. 
8.1 Case reports, human cohort and epidemiology studies 
There are relatively few reports of malignant tumours associated with total joint 
replacement (TJR) in humans, but the number of cases is increasing. Early published reports 
included cases of malignant soft tissue tumours such as chondrosarcoma, malignant fibrous 
histiocytoma, rhabdomyosarcoma, osteosarcoma and haemangio-endothelioma associated 
with joint replacement surgery (Swann, 1984, Jacobs et al., 1992). These have led to calls for 
the establishment of a central registry for implant related tumours (Apley, 1989). In 1992, the 
editor of a well established orthopaedic journal wrote ‘the 24 tumours thus far made public 
show no pattern in their histological type or in the timing of their appearance’. Nonetheless, 
he mentioned the importance of concerted efforts under way to accumulate cases of 
malignant neoplasms associated with TJRs, so as to better define the risks prospectively 
(Goodfellow, 1992).  
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During the past 30 years there have been sporadic case reports documenting the 
development of malignant neoplasms adjacent/proximate to artificial hips. Jacobs et al 
listed 18 reported cases in which malignancy was associated with MOM THRs. In most 
cases, malignant fibrous histiocytomas were reported at or near the femoral bone. The rest 
of the cases included osteosarcomas, fibrosarcomas or epitheloid sarcomas (Jacobs et al., 
1992). Five years later, Cole et al listed 23 hip implant related tumours; malignant fibrous 
histiocytoma in ten patients and osteosarcomas in four while malignant epithelioid 
hemangio-endothelioma, chondrosarcoma, fibrosarcoma, synovial sarcoma, spindle-cell 
sarcoma, epithelioid sarcoma and an adenocarcinoma had each been reported once. 
Interestingly, only in two of these cases the acetabulum was the primary tumour site (Cole 
et al., 1997). A relatively large number of case reports have described neoplasms originating 
from bone or soft connective tissue in the region of metal implants. However, a recent 
analytical study did not report an increased risk of soft-tissue sarcoma after metal implants 
(Adams et al., 2003). Notably, the study compared the incidence of soft-tissue sarcoma after 
metal implantation to the general population’s incidence of soft-tissue sarcomas, regardless 
of their presentation site. The results could possibly be much different if the comparison was 
made to the general population’s incidence of soft-tissue sarcomas solely at the hip region. 
There are few well documented cases of malignant lymphoma following THR surgery. 
Radhi et al reported the only case of soft tissue lymphoma in the quadriceps muscle 
overlying an implanted hip 4 years postoperatively (Radhi et al., 1998). Ito and Shimizu 
reported a case of non-Hodgkin’s lymphoma expanding from the ischium to involve the 
acetabular floor of an implanted THR (Ito & Shimizu, 1999). Ganapathi et al reported a B-cell 
lymphoma at the site of a chronic discharging sinus overlying a femoral periprosthetic 
fracture; the sinus formed at the time of the primary THR and continued to discharge for 12 
years, until the patient died (Ganapathi et al., 2001). Other cases reported have developed 
after chronic osteomyelitis (Dodion et al., 1982). Lymphomas and other cancers developing 
at a site of a metallic implant may theoretically result from the carcinogenicity of the 
metallic alloy, in particular from prostheses made of CoCr. However, there is growing 
evidence that some soft tissue malignant lymphomas occur after long standing antigenic 
stimulation in patients with a defective immune system (Radhi et al., 1998). Startlingly, 
regarding ceramics and carcinogenesis, there has been only one case report on an aggressive 
soft tissue sarcoma 15 months after implantation of a ceramic Ti-stem COP THR (Schuh et 
al., 2004). However, this could be due to the fact that COC articulations have only recently 
been re-introduced for clinical use, therefore there is a limited experience with ceramics in 
comparison to metals. 
It has been suggested that given the small number of reported cases of tumours around THR 
implants over the vast number of THRs performed, an association between joint 
replacement and local malignancy may be coincidental (Goodfellow, 1992). However, if one 
considers that wear debris from hip prostheses do not stay bound to periprosthetic tissues 
but disseminate throughout the body and accumulate in tissues/organs far from the hip, it 
is evident that looking for tumours only adjacent to the prostheses to draw conclusions as to 
the carcinogenicity of THR implants is not enough. To establish whether a link exists 
between such implants and malignancy, one must look at large scale epidemiology studies. 
In 1988, Gillespie et al studied more than 1000 patients and acknowledged the incidence of 
cancer 10 years after total hip replacement. There was a 3-fold increase in the prevalence of 
leukaemia and lymphomata in patients with Co-alloy THRs along with a puzzling decrease 
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in the incidences of breast and colon cancer. The authors hypothesised that chronic 
stimulation of the immune system from soluble and particulate wear of metal-on-metal 
THRs could encourage the emergence of lymphoreticular malignancies but increased 
immune surveillance could also inhibit the development of certain epithelial cancers 
(Gillespie et al., 1988). In a follow-up study, Visuri et al reported similar findings (Visuri & 
Koskenvuo, 1991). A later cohort study (Mathiesen et al., 1995) failed to confirm an 
increased prevalence of haematological malignancies following THR however, the number 
of patients followed was small and the post-operative follow up period of the patients was 
rather short. Nyren et al included a greater number of patients but still failed to link 
haematological malignancies with MOM implants. Instead, the authors reported a small but 
significant increase in kidney and prostate cancers in patients with THR (Nyren et al., 1995). 
A more recent study with over 400 patients, compared the incidence of cancer (9.5 years 
post-operatively) in patients with MOM or MOP articulations with that of the general 
population. Supporting Gillespie’s puzzling findings, the authors reported that the total 
cancer incidence in both groups of patients was less than expected in the general population. 
Nonetheless, a significant increase in the incidence of leukaemia and lymphomas was 
shown for patients with MOM prosthesis only (Visuri et al., 1996).  
In 1996, Gillespie et al presented an overview of the 4 relevant epidemiological studies 
published before mid 1995 with conflicting results. The results of the two earlier studies 
(Gillespie et al., 1988, Visuri & Koskenvuo, 1991) suggested a sustained increase in the risk 
of lymphoma and leukaemia after THR while the results of the two more recent studies 
(Mathiesen et al., 1995, Nyren et al., 1995) did not confirm this; although in one of them an 
increased risk was observed in the first year after implantation. The authors mention that 
‘the heterogeneity may be statistical in origin, but could also have a biologic explanation in 
the greater proportion of metal on metal prostheses used before 1973 (Gillespie et al., 1996). 
Gillespie et al had also performed 2 matched cohort studies and a case control study. In 
conclusion, neither the results of the matched studies of patients (operated on after 1973) nor 
the results of the latter 2 published epidemiological studies indicated a significantly 
increased risk of lymphoma or leukaemia following THR. Nonetheless, Gillespie et al 
tactfully advised that ‘if metal on metal articulations were to be reintroduced, careful 
surveillance would be essential’. As joint replacement surgery is becoming one of the most 
common surgical procedures, the widespread epidemiological debate on the frequency of 
haematological malignancies in these patients remains to date. 
The IARC has recently reviewed the epidemiological data for the risk of malignancy after 
THR (McGregor et al., 2000). It was noted that epidemiology studies compared patients with 
orthopaedic implants with the general population, thus failing to take into consideration 
several possible confounding factors/variables (e.g. immunosuppressive therapy, 
prevalence of rheumatoid arthritis). Moreover, the follow up period of most studies was 
considered to be too short after exposure to investigate the development of cancer, as 
carcinogens usually have a long latency period (i.e. the time from exposure to a carcinogen 
until the clinical presentation of a tumour/malignancy). Asbestos particles for example are 
known to produce cancer between 22 and 37 years after exposure (Barrett, 1994). It was also 
noted that the mutagenicity and carcinogenicity of biomaterials are influenced by their exact 
composition, their surface properties, the composition and rate of release of leachable 
materials, the physical environment and degradation (which may lead to formation of 
www.intechopen.com
 
The Genotoxic Potential of Novel Materials Used in Modern Hip Replacements for Young Patients 
 
115 
compounds with different mutagenic properties). Therefore, since most epidemiology 
studies of orthopaedic implants have not taken into account the type of metal alloy used in 
each case, most of this information was considered inadequate. Unfortunately, no 
epidemiological data relevant to the carcinogenicity of ceramic implants is available to date. 
Therefore, orthopaedic implants according to IARC remain non-classifiable (WHO, 1999). 
In molecular epidemiology, the occurrence of DNA damage has been explored for its links 
to the development of cancer. The frequency of cells with structural chromosomal 
aberrations in peripheral blood lymphocytes is the first genotoxicity biomarker that has 
shown a clear association with cancer risk. In two separate large (>1500 subjects) cohort 
studies, the level of chromosomal aberrations in peripheral blood lymphocytes was 
measured in healthy individuals at the start of the study, and the development of cancer 
was monitored over several decades. High levels of chromosomal aberrations were clearly 
associated with increased total cancer incidence in one cohort and increased total cancer 
mortality in the other cohort, suggesting that DNA lesions responsible for chromosomal 
aberrations are clearly associated with cancer risk (Hagmar et al., 2004). An important 
preliminary cohort study by Case et al used blood and bone marrow samples from 71 
patients at revision arthroplasty and 30 controls (prior to primary arthroplasty) to test for 
chromosomal aberrations. Cells adjacent to the prosthesis had a higher chromosomal 
aberration rate compared to that seen in iliac crest bone marrow cells from the same patients 
at revision surgery. Both samples taken at revision surgery had higher chromosomal 
aberration rates than those seen preoperatively in femoral bone marrow cells in controls. 
The authors also noted the occurrence of clonal expansion of lymphocytes in 2 out of 21 
patients studied at revision arthroplasty, which was performed more than 10 years after 
primary THR (Case et al., 1996). In a follow-up study, Doherty et al used peripheral blood 
lymphocytes from 31 MOM THR patients presenting at revision and over 30 controls (prior 
to having a THR) for cytogenetic analysis. They showed that at revision arthroplasty there 
was a 3-fold increase in aneuploidy and a 2-fold increase in random chromosomal 
translocations which could not be explained by confounding variables (smoking, gender, 
age and diagnostic radiographs). Most interestingly, metal alloy specific differences were 
seen: In the lymphocytes of Ti-alloy prostheses recipients there was a 5-fold increase in 
aneuploidy but no increase in chromosomal translocations; by contrast, in the lympocytes of 
CoCr-alloy recipients there was a 2.5 fold increase in aneuploidy and a 3.5 increase in 
chromosomal translocations. In lymphocytes from patients with stainless steel prostheses 
there was no increase in either aneuploidy or chromosomal translocations. Therefore, the 
authors suggested that although chromosomal translocations and aneuploidy can be seen in 
normal (non-THR) patients and are known to accumulate with time, genetic changes in THR 
patients may depend on the type of prosthesis (Doherty et al., 2001). Finally, in a more 
recent prospective study, Ladon et al investigated changes in metal levels and chromosome 
aberrations in patients within 2 years of receiving MOM THRs. A statistically significant 
increase of both chromosome translocations and aneuploidy was seen in peripheral blood 
lymphocytes at 6, 12 and 24 months post-operatively. The changes were generally 
progressive with time but the change in aneuploidy was much greater than in chromosome 
translocations. Although there was a significant increase of both Co and Cr ion 
concentrations, no significant correlations were found between chromosome translocation 
indices and Co or Cr concentration in whole blood while the clinical consequences of these 
observed changes remain unknown (Ladon et al., 2004). 
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8.2 Animal studies  
In vivo investigations into the carcinogenicity of orthopaedic implant related materials were 
undertaken as early as the 1950s, prompted by the clinical observation that workers in nickel 
and chromate refining/smelting plants had increased risks of nasal and lung tumours. 
Oppenheimer et al were the first to clearly establish the potential carcinogenicity of 
implants: they placed various metal foils subcutaneously in rats and observed malignant 
tumours develop (Oppenheimer et al., 1956). One year later, Heath et al observed 
rhabdomyosarcomas following intramuscular injection of Co powder in more than half of 
the rats studied (Heath, 1957). Heath et al also demonstrated the development of sarcomata 
in rats bearing CoCrMo wear particles from total joint prostheses (Heath et al., 1971). 
However, tumourigenesis due to CoCrMo could not be confirmed in later studies by 
Meachim (Meachim et al., 1982). 
Swanson et al were the first to test wear debris collected directly from orthopaedic implants. 
They used simulators to produce Vitallium (CoCrMo) powder, resuspended it in horse 
serum and injected it into rats; local sarcomas developed in 15 of 41 animals within 4-18 
months (Swanson et al., 1973). In 1977, Gaechter et al used intramuscular implantation of 
solid alloy implants but, after evaluating seven alloys (260 animals in total) for 2 years, 
failed to demonstrate a carcinogenic hazard. Notably, they recorded 19 malignant sarcomas, 
all remote from the implantation site (Gaechter et al., 1977). In a follow up study, Memoli et 
al implanted rats with a variety of alloys in solid rod, powdered and sintered aggregate 
form and observed the animals (until they died or) for 30 months. A slight increase in 
sarcomata was noted in rats bearing metal alloy implants with high contents of Co, Cr or Ni 
and the development of lymphomas with osseous involvement was also more common in 
these animals. Interestingly, tumours were more commonly seen in rats that received 
(metal) powders compared to those that received rods or sintered implants (Memoli et al., 
1986). Howie et al published a contradictory study on the effects of intra-articular CoCr-
alloy wear particles in rats, where they noted no tumours after observing the animals for 
more than 1 year (Howie & Vernon-Roberts, 1988). Although carcinogenicity of various 
(mostly metal) implant materials has been documented in several animal studies, a more 
recent study investigating the carcinogenic effects of intra-articular powder administration 
of CoCrMo and TiAlV alloys in rats disputed these early findings, suggesting that such 
particles if carcinogenic are only weakly so (Lewis et al., 1995). The authors used particulate 
wear debris created in a simulator and observed the animals for 2 years (or until there was 
evidence of tumours). The negative carcinogenesis results of this study should be 
interpreted with caution, since the number of animals used per experimental group was low 
(8-12 rats), and the observation period was rather short. Bouchard et al assessed the 
carcinogenicity of CoCrMo versus TiAlV implants in a long-term study in rats. Importantly, 
the existence of implant associated tumours correlated with loose implants; none with well 
fixed in situ implants. Histologically the tumours were categorized as dermatofibrosarcoma, 
fibrosarcoma, malignant histiocytoma, lymphoma and osteosarcoma, seen both adjacent to 
the implantation site and in remote sites - most prevalent in the pituitary and mammary 
glands. The authors suggested a foreign-body (immunological) reaction as the primary 
mechanism of carcinogenesis, as a significantly increased accumulation of chronic 
inflammatory tissues was seen around loose rather than fixed implants (Bouchard et al., 
1996). Animal studies using alumina ceramics as implant materials are virtually absent from 
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the literature, however, in one study in rats subcutaneous implantation of discs of 
aluminium oxide ceramic produced local sarcomas (Kirkpatrick et al., 2000).  
There are many limitations as to what extent the carcinogenicity of human THR implants 
can be evaluated in animal studies. First of all, there are differences in the composition of the 
materials tested, although this is not surprising given the developments in the production of 
implants over the years. There are also some differences in the methods of preparation of 
materials for administration but mainly there is great variation in the proposed routes of 
administration and the site(s) of implantation. A priori, the intra-articular route of 
administration seems to be the most appropriate for arthroplasty carcinogenesis models and 
as early as 1988 intraarticular injections had been proposed as the route of choice for such 
studies (Howie & Vernon-Roberts, 1988). Furthermore, there is observed variation as to the 
physical form (foils, solids, particles) of the materials used and an increasing trend to use 
small particulates rather than solid implants; possibly since the important role of wear 
particles for implant failure in THR was recognized. Finally, the differences in the periods of 
time that the animals were observed following implantation and in the number of animals 
that were used in each case make critical evaluation of such studies difficult. The relevance 
of animal models for evaluation of THR cancer risk in humans is still questionable, 
especially as it is well documented that different animals and even strains/species of the 
same animal have different susceptibility to tumour formation (Gibb, 1992). Several calls 
and recommendations for the ‘standardization’ of animal carcinogenicity studies have been 
made (Courtland & William, 1996). Importantly, the IARC recently states ‘despite the large 
number of animal studies, none have proven truly conclusive as to the carcinogenicity of 
implant materials, resulting only in indefinite statements at best regarding excessive tumour 
formation in animals exposed to wear debris from orthopaedic implants’ (WHO, 1999).  
8.3 In vitro studies  
A cancerous substance is termed capable of inducing a cancerous phenotype; for in vivo 
evaluations this means the induction of solid tumours and/or haematological malignancies 
while in cell culture models scientists look for cancer biomarkers and/or neoplastic 
transformation. The latter is an attainment of certain heritable characteristics from a cell, 
such as loss of contact inhibition and continuous growth/division, which can lead to clonal 
expansion. Neoplastic transformation is often the result of one or more heritable genetic 
alterations and in fact all recognized carcinogens are also genotoxic. Thus, in vitro testing of 
potential carcinogens has initially largely relied on the use of several genotoxicity tests (e.g. 
the Ames test, which measures the ability of a chemical to induce mutations in bacteria). On 
the other hand, not all acquired genetic alterations lead to neoplastic transformation (i.e. 
cancerous phenotypes) hence not all mutagens/genotoxins are carcinogens. Concerns for 
the potential carcinogenicity of THR implants relate mostly to the systemic existence of both 
soluble and particulate wear debris for long periods of time following implantation. Even 
for successful THRs the generation of mode 1 wear from the intended ball-on-socket 
articulation (see section 5) is inevitable and so is its dissemination throughout the body. 
Currently, due to their low wear rates, the preferred articulating couples for implantation in 
young patients are MOM (mainly CoCr alloy) and COC (mainly alumina). Unlike ceramics, 
there is a long clinical experience with metals. However, the genotoxicity of orthopaedic 
metal alloys has been investigated in-vitro mainly by testing their soluble ions, since until 
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recently it has always being assumed that the effects of metal particles could be attributed 
solely to their ionic form(s). Lison et al have shown this to be a misjudgement when they 
showed that Co metal particles induced DNA damage via free radicals by a mechanism 
which was independent of the existence of soluble Co (II) ions; in fact they proved that Co 
atoms from the surface of the particle were able to reduce oxygen, thus forming reactive 
oxygen species (ROS) (Lison et al., 2001). Notably, there are only a few in-vitro studies 
relevant to the potential carcinogenicity of orthopaedic metals which employed metal 
particulates rather than their ions.  
Particulate corrosion debris from metal bearings includes insoluble metal salts. Patierno et al 
actually indicated that the water-insoluble (particulate) Cr VI salts are more potent 
carcinogens than the water soluble ones, since only the particulate Cr (VI) compounds 
induced neoplastic transformation of mouse embryo cells (Patierno et al., 1988). In later 
studies, Wise et al used chromosome damage as a measurable genotoxic endpoint to study 
the genotoxicity of both particulate and soluble Cr (VI) in primary human bronchial 
fibroblasts at concentrations of low, medium and high toxicity. The scientists used lead 
chromate (PbCrO4) and sodium chromate (Na2CrO4) as prototypical particulate and soluble 
Cr VI salts, respectively, to show that the amount of chromosomal damage increased with 
increasing concentrations after 24h to both compounds (and so did the cytotoxicity levels) 
(Wise et al., 2002). Other studies have showed that metallic Co particles were able to induce 
DNA breaks and micronuclei in human peripheral lymphocytes in a dose dependent 
manner (Anard et al., 1997, Van Goethem et al., 1997). De Boeck et al showed that despite a 
relatively large interexperimental and interdonor variability, the DNA-damaging potential 
of the Co-tungsten carbide mixture was higher than that of Co metal and Co chloride which 
had comparable responses (De Boeck et al., 2003). Metallic Co and its compounds without 
tungsten carbide are classified by the IARC as being ‘possibly carcinogenic to humans’ 
(WHO, 1991) while Co metal containing tungsten carbide was recently classified as 
‘probably carcinogenic to humans’ (WHO, 2006). 
Perhaps the most relevant study to the potential carcinogenicity of CoCr-alloy wear debris 
was performed by Davies et al; using primary human fibroblasts as a cell culture model the 
authors reported on metal-specific differences in the level/types of DNA damage induced 
by synovial fluid retrieved at revision surgery from 24 patients. Synovial fluid taken during 
revision surgery from all 6 samples from CoCr MOM prostheses and 4 of 6 samples from 
CoCr MOP prostheses, but none of 6 samples from stainless steel MOP prostheses caused 
significant DNA damage. Particulate-free samples of phosphate buffered saline where CoCr 
alloy was left to corrode also caused DNA damage and the authors suggested that this 
depended mainly on a synergistic effect between the Co and Cr ions produced by corrosion 
(Davies et al., 2005). Notably, the retrieved synovial fluid is thought to contain both soluble 
and particulate CoCr-alloy wear debris. Studies from our group have shown that CoCr alloy 
particles cause genotoxic damage in primary human fibroblasts while factors such as 
particle size and cell age may influence the genotoxic outcomes (Papageorgiou et al., 2007a, 
Papageorgiou et al., 2007b). There is a lack of in vitro carcinogenicity and/or genotoxicity 
studies for particulate alumina. Alumina’s biocompatibility has been evaluated by Takami 
et al using the Ames test in bacteria; no mutagenic activity was observed in 5 tester strains of 
Salmonella typhimurium. In addition, no cytotoxicity was observed in mouse fibroblast cells 
following incubation with Al2O3 disks in cultures for up to 48 hours (Takami et al., 1997). 
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However, a more relevant study by Dopp et al reported that alumina ceramic fibres were 
genotoxic to human amniotic fluid cells causing both numerical and structural chromosomal 
aberrations (Dopp et al., 1997). More recently, our group has shown that alumina particles 
can be genotoxic to human cells in vitro (Tsaousi et al., 2010). 
The cellular mechanisms of carcinogenesis have been the subject of a vast amount of in vitro 
studies in the field of cancer research. Such studies have elucidated the cause-effect links for 
most of the recognized human carcinogens. Interestingly, out of all listed carcinogens to 
date (according to the IARC), asbestos is the only substance of a ‘particulate’ nature. Studies 
investigating the effects of particulate matter in relation to lung cancer have shown that the 
carcinogenicity of particles and/or fibres follows different rules to chemical carcinogenesis. 
Particles and fibres form a rather specific group among all toxicants, and their 
physicochemical behaviour in genotoxicity tests is usually very different from that of soluble 
chemicals, especially the nature of their interaction with DNA. During/after exposure, 
chemicals may interact directly with DNA and/or indirectly (e.g. following metabolic 
activation and/or cell signalling events). On the other hand, particulate matter is thought to 
interact with DNA only following internalization (i.e. phagocytosis), while indirect action on 
DNA is possible without the need for metabolic activation (e.g. via formation of ROS related 
to surface properties and/or interaction with mitotic spindle apparatus). Another major 
difference is seen in the kinetics of exposure. Chemicals show a classical pharmacokinetic 
behaviour: distribution, biotransformation, elimination. Particulate kinetics on the other 
hand depends on deposition, clearance, durability, overload, etc. Furthermore, particulates 
are believed to have a ‘carrier’ function in vivo (Donaldson & Stone, 2003, Speit, 2002, 
Oberdorster, 2002).  
Both CoCr alloy and ceramic THR systems are ‘not yet classifiable as to their carcinogenicity 
to humans’, although Cr (VI) is accepted around the world as a human lung carcinogen 
(WHO, 1990) and soluble Co (II) salts have recently been classified as possibly carcinogenic 
to humans (WHO, 2006). This may be in part due to the lack of enough convincing evidence 
that CoCr particulate wear debris can be genotoxic. However, for ceramic THR systems, the 
main reason is probably that they have only recently been introduced to the market. In vitro 
studies from our group have shown that both CoCr alloy and Al2O3 particles are genotoxic 
to human cells (Papageorgiou et al., 2007a, Tsaousi et al., 2010). Importantly, it has recently 
been shown that cobalt-chromium nanoparticles can damage human cells across an intact 
cellular barrier without having to cross the barrier, by intercellular signaling possibly 
through cell-cell junctions (Case et al, 2009).  
9. Conclusion 
THR is generally considered as a treatment option when pain is so severe that it impedes 
normal function despite the use of anti-inflammatory medication. As an elective procedure, 
it is a decision reached after careful consideration of its comparative benefits over its 
potential risks. When the editor of JBJS invited surgeons to submit reports of any tumour 
associated with replaced joints he wrote ‘although the benefits of joint replacement might 
outweigh any risks a thousand-fold, that is no excuse for suppressing the facts’. As modern 
non-corroded MOM and COC THRs commonly used for young patients will still inevitably 
generate particulate wear over time, it is our belief that research should focus more on its 
long-term genotoxicity and therefore carcinogenic potential. The genotoxicity of different 
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materials should also be taken into account for the design and development of all prosthetic 
implants. Finally, THR surgeons should consider lifestyle factors further than the levels of 
physical activity such as the likelihood of having children. 
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